<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567489</url>
  </required_header>
  <id_info>
    <org_study_id>31998</org_study_id>
    <nct_id>NCT00567489</nct_id>
  </id_info>
  <brief_title>IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients</brief_title>
  <acronym>Impendia</acronym>
  <official_title>Multi-Center, Prospective, Randomized Trial To Demonstrate Improved Metabolic Control of PEN VS Dianeal Only in Diabetic CAPD and APD Patients - The Impendia Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal
      only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and
      Automated Peritoneal Dialysis (APD)patients leads to improved metabolic control as measured
      by the magnitude of change from the baseline value in the HbA1c levels.

      Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs Dianeal
      only) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower glycemic-control
      medication requirements, decreased incidence of severe hypoglycemic events requiring medical
      intervention, improved metabolic control, nutritional status, and Quality of Life. In a
      subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs Dianeal only) on
      abdominal fat and left ventricular (LV) structure and function will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the baseline value in HbA1c between the PEN group compared to the Dianeal only group</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control medication usage, hypoglycemic events, metabolic control, nutritional status, and QOL.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>ESRD</condition>
  <condition>Diabetes</condition>
  <condition>CAPD</condition>
  <condition>APD</condition>
  <arm_group>
    <arm_group_label>Non glucose sparing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dianeal only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glucose sparing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEN solutions: Nutrineal, Extraneal, and Physioneal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physioneal</intervention_name>
    <description>Physioneal 40 or Physioneal 35</description>
    <arm_group_label>glucose sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dianeal</intervention_name>
    <description>Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)</description>
    <arm_group_label>Non glucose sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extraneal</intervention_name>
    <description>7.5% Icodextrin</description>
    <arm_group_label>glucose sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nutrineal</intervention_name>
    <description>Amino Acids 1.1%</description>
    <arm_group_label>glucose sparing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. M/F patients 18 years of age or older

          2. Diagnosis of ESRD (GFR ≤ 15 mL/min)

          3. CAPD or APD using only Dianealand/or Physioneal, at least 1 exchange of 2.5% or 4.25%
             dextrose/day, no prescribed dry time

          4. DM (Type 1 and 2) on glycemic-control medication, for 90 days

          5. HbA1c &gt; 6.0% but ≤ 12.0%

          6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL

        Exclusion Criteria:

          1. Cardiovascular event within the last 90 days

          2. Ongoing clinically significant congestive heart failure (NYHA class III or IV)

          3. Allergy to starch-based polymers

          4. Glycogen storage disease

          5. Maltose, or isomaltose intolerance

          6. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30
             days

          7. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP &lt; 77) at Screening.

          8. Serum urea &gt; 30 mmol/L

          9. Exposure to Extraneal or Nutrineal within the last 60 days prior to Screening visit,
             Day 1.

         10. Receiving rosiglitazone maleate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter Healthcare Corporation</last_name>
    <role>Study Director</role>
    <affiliation>Call central contact for information</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <state>N.t.</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Tai Po</city>
        <state>N.t.</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwong Wah Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Chung-Gu</city>
        <state>Deagu</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Fatima Hospital</name>
      <address>
        <city>Dong-gu</city>
        <state>Deagu</state>
        <zip>701-600</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Nam-gu</city>
        <state>Deagu</state>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University of Medical Center Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Hospital # 52</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Hospital n a S P Botkin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Research n a M F Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Institution: &quot;Municipal Clinical Hospital #7 &quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Hospital n a M I Kalinin</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg Mariinskaya Hospital</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg St Elizabeth Hospital</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
  </removed_countries>
  <reference>
    <citation>Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int. 1999;19 Suppl 3:S35-42; discussion S43.</citation>
    <PMID>10433550</PMID>
  </reference>
  <reference>
    <citation>Delarue J, Maingourd C, Couet C, Vidal S, Bagros P, Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int. 1998 Sep-Oct;18(5):505-11.</citation>
    <PMID>9848629</PMID>
  </reference>
  <reference>
    <citation>Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int. 2000;20 Suppl 2:S37-41. Review.</citation>
    <PMID>10911641</PMID>
  </reference>
  <reference>
    <citation>Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant. 2006 Feb;21(2):494-8. Epub 2005 Oct 12.</citation>
    <PMID>16221697</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003 Jan;26 Suppl 1:S33-50. Erratum in: Diabetes Care. 2003 Mar;26(3):972.</citation>
    <PMID>12502618</PMID>
  </reference>
  <reference>
    <citation>Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif. 2005;23(4):303-10. Epub 2005 Jun 23.</citation>
    <PMID>15980620</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESRD</keyword>
  <keyword>Diabetes</keyword>
  <keyword>CAPD</keyword>
  <keyword>APD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 14, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

